Media contributions
1Media contributions
Title Almac Diagnostics Leverages TruSight® Tumour 170 to Advance Clinical Research Degree of recognition International Media name/outlet Illumina Media type Print Country/Territory United Kingdom Date 31/03/2017 Description The recently launched TruSight Tumor 170 integrates DNA and RNA into one protocol to accelerate comprehensive analysis of cancer-related variants and maximize the data obtainable from precious specimens. Designed to support limited nucleic acid input (40ng of DNA and RNA) from formalin-fixed, paraffin-embedded (FFPE) samples, TruSight Tumor 170 facilitates efficient evaluation of biomarkers URL https://www.illumina.com/company/news-center/feature-articles/trusight-tumor-170-beta-site-interview.html Persons Paul Harkin